Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...

Investing.com – U.S. stocks were higher after the close on Friday, as gains in the Industrials, Utilities and Basic Materials ...

In a report released today, Sarah Schram from William Blair maintained a Buy rating on Ovid Therapeutics (OVID – Research Report). The company’s shares closed yesterday at $0.49. Effectively ...

Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...

A digital therapeutics start-up which uses augmented reality (AR) glasses to aid people suffering from disorders including Parkinson's disease and multiple sclerosis will this week announce a £ ...

About Checkpoint Therapeutics, Inc. Checkpoint is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments ...

1 GKE cluster on GCP 1 Kops on GCE cluster Istio (Dual control plane, single mesh) Anthos Config Management (both clusters configured for the same config repo) GKE Connect installed on both clusters ...

A high throughput screen of >30,000 diverse repressor domains from across the tree of life identifies repressor domains with unique structures that underpin enhanced epigenetic effector domain ...

Roche secures Zealand obesity drug candidate for up to $5.3 billion Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as ...